Lynn Quincy, Consumers Union
Gary Claxton, Kaiser Family Foundation
Only 11 of the not-for-profit health plans are still operating, and the program that would cushion them from financial losses is in trouble. Will it be fixed?
Pharmaceutical companies still hold important cards when it comes to negotiating prices, but that may change with new ways of measuring value.
James Helstrom, CMO of Fox Chase Cancer Center
At last there is a treatment for the inherited condition that affects bone development. But at $300,000 per year, cost is a major issue.